Strontium-89 Therapy

Strontium-89 Therapy is a form of radionuclide therapy that utilizes the beta-emitting isotope strontium-89 to selectively target and ablate bone metastases by mimicking calcium uptake in areas of increased osteoblastic activity.

170

Publications

7.6K

Citations

702

Authors

265

Institutions

Publications per year

2017–2026

7

Variants

89Sr Therapy

Authors

702

  1. AM
    Alexander McEwan

    University of Alberta, Canada

    7 publications · 1.4K citations

    7

    h-index

  2. AT
    Arthur T. Porter

    Wayne State University, United States

    6 publications · 978 citations

    6

    h-index

  3. DM
    D. M. Ackery

    Southampton General Hospital, United Kingdom

    6 publications · 749 citations

    6

    h-index

  4. MA
    Maureen A. Zivanovic

    Southampton General Hospital, United Kingdom

    6 publications · 896 citations

    6

    h-index

  5. VL
    Valerie Lewington

    Royal Marsden NHS Foundation Trust, United Kingdom

    6 publications · 920 citations

    6

    h-index

1–5 of 702

Venues

  1. PubMed

    Repository · 31 publications · 1.1K citations

    19

    h-index

  2. 12

    h-index

  3. 6

    h-index

  4. Cancer

    6 publications · 202 citations

    6

    h-index

  5. British Journal of Radiology

    BJR · 6 publications · 339 citations

    6

    h-index

1–5